Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer

NCT03490292 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT03490292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03490292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1/2
Overall status
Completed
Start date
May 29, 2018
Completion date
July 12, 2023
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal cancer, resectable esophageal cancer